Needham & Company LLC Reiterates Hold Rating for Hologic (NASDAQ:HOLX)

Hologic (NASDAQ:HOLX)‘s stock had its “hold” rating reiterated by equities researchers at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports.

HOLX has been the topic of a number of other reports. Mizuho set a $75.00 price objective on Hologic in a research note on Thursday, July 31st. Weiss Ratings restated a “hold (c-)” rating on shares of Hologic in a research report on Wednesday, October 8th. Stephens reissued an “overweight” rating and issued a $78.00 price target on shares of Hologic in a research note on Thursday, September 18th. Morgan Stanley raised their price objective on shares of Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a research report on Thursday, July 31st. Finally, Argus raised their price objective on Hologic from $80.00 to $90.00 and gave the company a “buy” rating in a report on Friday, September 19th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $79.00.

Hologic Stock Performance

NASDAQ:HOLX opened at $73.93 on Tuesday. The business has a fifty day simple moving average of $67.41 and a two-hundred day simple moving average of $63.76. Hologic has a 1 year low of $51.90 and a 1 year high of $84.39. The company has a market capitalization of $16.44 billion, a P/E ratio of 30.68, a P/E/G ratio of 2.54 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the previous year, the business posted $1.06 EPS. The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, analysts expect that Hologic will post 4.28 earnings per share for the current year.

Insider Activity at Hologic

In related news, Director Christiana Stamoulis sold 7,402 shares of Hologic stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the transaction, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.88% of the company’s stock.

Hedge Funds Weigh In On Hologic

Hedge funds have recently modified their holdings of the company. Chung Wu Investment Group LLC bought a new position in shares of Hologic during the second quarter valued at about $26,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares during the last quarter. SJS Investment Consulting Inc. increased its holdings in Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 362 shares during the period. Loomis Sayles & Co. L P bought a new position in Hologic during the 2nd quarter valued at approximately $33,000. Finally, Zions Bancorporation National Association UT purchased a new stake in Hologic in the 1st quarter worth approximately $34,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.